Vanguard Capital Management’s Teva Pharmaceuticals TEVA Stock Holding History

Vanguard Capital Management’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$89.9K	Buy	+2,654	New	+$88.4K	﹤0.01%	3884

Other funds holding TEVA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

HIIFS

Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return

Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return

WCM Investment Management Laguna Beach, California $55.2B AUM 57.07% 1-Year Est. Return

Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return

MMH

Menora Mivtachim Holdings Ramat Gan, Israel $25.6B AUM 50.04% 1-Year Est. Return

MIFH

Migdal Insurance & Financial Holdings Petach Tikva, Israel $15.6B AUM 71.29% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

LIM

Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return

Vanguard Capital Management's TEVA Position: Q2 2026 in Review

Vanguard Capital Management opened a new position in Teva Pharmaceuticals (TEVA) in Q2 2026: 2,654 shares worth $89.9K. The stake represents ﹤0.01% of the portfolio and ranks #3884 among its holdings.

671 funds tracked by Wall St. Rank hold TEVA as of Q2 2026.

Vanguard Capital Management held 2,654 shares of Teva Pharmaceuticals worth $89.9K as of Q2 2026.
Teva Pharmaceuticals was a new Vanguard Capital Management position in Q2 2026.
Teva Pharmaceuticals made up ﹤0.01% of Vanguard Capital Management's portfolio in Q2 2026, its #3884 holding.
671 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2026.

Based on Vanguard Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.